The Nusano Medical Radioisotopes Advisory Board works to keep the company apprised of emerging industry trends, guide the development of isotopes for next-generation theranostic compounds, and identify ways to better serve cancer patients. We are honored to have these leaders in healthcare and industry providing their input as Nusano works to supply the fight against cancer by making medical radioisotopes available and abundant.

Munir Ghesani, MD, FACNM, FACR, FSNMMI, is the Medical Director of United Theranostics in Princeton and the Chief Medical Officer of United Theranostics. He previously served as the Systems Chief of Nuclear Medicine and Molecular Imaging at Mount Sinai Health System in New York. Dr. Ghesani has been actively involved in clinical practice, research, clinical trials, and education for over 25 years, primarily focusing on nuclear medicine, molecular imaging, and targeted radiopharmaceutical therapies.

 Dr. Ghesani has authored more than 200 publications in peer-reviewed journals and is the Editor-in-Chief of a three-part book on nuclear medicine and molecular imaging. He has delivered over 150 presentations at regional, national, and international conferences.

Dr. Ghesani has held leadership roles in various societies and colleges, including Immediate Past President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Past-President of the Education and Research Foundation of Nuclear Medicine and Molecular Imaging, Past Chairman of the American Board of Nuclear Medicine, Past Chairman of the Government Relations Committee, and the FDA Task Force of the SNMMI, as well as Past Chairman of the Nuclear Medicine and PET Accreditation Committee of the American College of Radiology. In January 2020, he was awarded the ACNM Personal Best Mentor of the Year. He has also been recognized as a Fellow of the American College of Nuclear Medicine (2006), the American College of Radiology (2018), and the Society of Nuclear Medicine and Molecular Imaging (2023).

Suzanne E. Lapi, Ph.D. is the Emmet O’Neal II Professor, O’Neal Comprehensive Cancer Center and Professor of Radiology and Chemistry and Cyclotron Facility Director at the University of Alabama at Birmingham. She is also the Vice Chair of Research in the Department of Radiology. Her research interests are in the development and translation of new PET radionuclides and molecular imaging agents. She has over 150 publications and is principal investigator on active research grants from the National Institutes of Health (NIH) and United States Department of Energy (DOE), as well as industry partners. She oversees production of PET radionuclides and imaging radiopharmaceuticals for preclinical research and clinical trials. Her group holds more than 15 approved INDs and supplies Cu-64, Zr-89, Mn-52 and other isotopes to groups across the USA and internationally. She is a Fellow of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and a strong advocate of radiopharmaceutical sciences and the training of future nuclear and radiochemists at the graduate, postdoctoral and faculty levels.

The CEO of the XCancer® Organization, Dr. Luke Nordquist is a practicing Medical Oncologist with an expertise in prostate cancer. Nordquist’s Community Cancer Center in Omaha, Neb. Is internationally known, gaining recognition for its participation in early and late phase radiopharmaceutical trials of Ra-223, Lu-177, Ac-225, Th-227, Pb-212, Zr89, In111, Cu-64, and Cu-67. Nordquist and his XCancer team have conducted over 40 imaging & therapeutic Theranostic trials to date including 22 Firsts-in-World trials. His research program is recognized for rapid start-ups, high accruals, and exceptional data timeliness and quality. Dr. Nordquist is also the Founder of TheranosticTrials.Org, a digital platform increasing education and access of global Theranostic trials. Through his XCancer® Research Network, Nordquist is working to provide access to cutting edge clinical trials closer to home. In so doing, he and his collaborators are to increase community cancer center participation and drive improved access for cancer patients regardless of geography.

Dr. Koo is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, AZ. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr. Koo’s academic interests have focused on nuclear medicine in prostate cancer and response to novel therapies using PET, with over 80 peer reviewed publications and abstracts. He has lectured nationally and internationally on topics related to imaging and radiopharmaceutical based therapies in prostate cancer. Dr. Koo is the Founding Chair of the SNMMI Therapeutics Conference and was the recipient of the SNMMI Presidential Distinguished Service Award in 2022.

Neal Shore, MD, FACS, graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center. Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, the APCCC Scientific Steering Committee, Maple Tree Cancer Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and the co-chair of the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP, Everyday Urology Oncology and World Journal of Urology. He is the Editor-in-Chief of Reviews in Urology . He is a Fellow of the American College of Surgeons and a Certified Physician Investigator.